--- title: "Nonsense - Pharmaceuticals" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/33934960.md" description: "Benefiting from local R&D demand: $Regeneron Pharma(REGN.US) Logic: Strong in-house R&D engine, focusing on ophthalmology, immunology, and oncology. Its independent innovation capability becomes an advantage amid the trend of reducing external dependence. Highlights: Strong sales of star products Eylea and Dupixent, with a deep R&D pipeline. $Vertex Pharma(VRTX.US) Logic: Holds an absolute monopoly in the cystic fibrosis (CF) field, with ample cash flow. Actively expanding into non-CF areas (e.g., pain, kidney diseases)..." datetime: "2025-09-12T01:05:44.000Z" locales: - [en](https://longbridge.com/en/topics/33934960.md) - [zh-CN](https://longbridge.com/zh-CN/topics/33934960.md) - [zh-HK](https://longbridge.com/zh-HK/topics/33934960.md) author: "[奇迹的交易员cola](https://longbridge.com/en/profiles/10743314.md)" --- # Nonsense - Pharmaceuticals Benefiting from local R&D demand: - $Regeneron Pharma(REGN.US) - Logic: Strong in-house R&D engine, specializing in ophthalmology, immunology, and oncology. Its independent innovation capability becomes an advantage amid the trend of reducing external dependencies. - Highlights: Strong sales of star products Eylea and Dupixent, with a deep R&D. - $Vertex Pharma(VRTX.US) - Logic: Absolute monopoly in the cystic fibrosis (CF) field, with ample cash flow. Actively expanding into non-CF areas (e.g., pain, kidney diseases). - Highlights: The first gene-editing therapy in collaboration with CRISPR Therapeutics has been approved, representing future technological direction. - $Amgen(AMGN.US) - Logic: Among large pharmaceutical companies, it possesses strong biologics R&D and manufacturing capabilities. Its obesity drug MariTide is seen as a potential competitor to Eli Lilly and Novo Nordisk. - Highlights: Strengthened inflammatory disease product line after acquiring Horizon, with in-house manufacturing capabilities reducing supply chain risks. Benefiting from production reshoring: - $Thermo Fisher Scentific(TMO.US) - Logic: A global scientific services giant providing equipment, consumables, and CDMO services from R&D to production. It is the "shovel seller" of biotech infrastructure. - Highlights: Regardless of policy changes, its indispensable position in the industry remains solid. - $Novo Nordisk AS(NVO.US) Logic: A top global CDMO, specializing in biologics, cell and gene therapy, and oral/injectable manufacturing. Benefits from production reshoring. - $Danaher(DHR.US) - Logic: Its subsidiary Cytiva is a leading brand in bioprocessing equipment and consumables. Pharmaceutical companies expanding capacity will inevitably procure its products. - Highlights: Diversified and stable business, less affected by economic cycles. Clinical trial and data service leaders: - $IQVIA(IQV.US) - Logic: One of the world's largest CROs (Contract Research Organizations), providing clinical trial management, data analysis, and compliance consulting. The stricter the FDA's data standards, the more its value is highlighted. - Highlights: Possesses an irreplaceable real-world data (RWD) repository. - $Charles River Laboratorie(CRL.US) - Logic: Focuses on preclinical research (drug discovery, safety evaluation), the forefront of drug development. Localized innovative drug R&D will increase its demand. - Highlights: Early-stage offerings have pricing power and high barriers to entry. - $ROCHE HOLDINGS AG(RHHVF.US) - Logic: Dual core in diagnostics and pharmaceuticals. Diagnostics are critical for supply chain security, while the pharmaceutical division has a strong foundation in neuroscience and oncology. · Highlights: Extensive collaboration history with Chinese pharmaceutical companies, potentially serving as a bridge for "workaround" partnerships. Technology platform companies: - $BioNTech SE(BNTX.US) - Logic: Leader in mRNA technology platforms, actively developing applications beyond COVID-19 vaccines, such as cancer vaccines. - Highlights: Headquartered in Germany, with successful collaboration precedents in China (e.g., Fosun Pharma), a replicable model for other pipelines. - $Genmab A/S(GMAB.US) - Logic: Denmark's "Antibody King," with unique ADC (Antibody-Drug Conjugate) platform technology. - Highlights: Its platform is highly attractive to Chinese pharmaceutical companies seeking technological upgrades, with abundant licensing opportunities. - $Argenx(ARGX.US) - Logic: Belgian immunology company; its FcRN inhibitor Vyvgart has proven its innovative capabilities. - Highlights: Represents the rise of mid-sized European biotech innovators, with pipeline revaluation potential. Investment strategy recommendations: > - Diversify: Avoid betting on a single company; build a portfolio by industry role (R&D, manufacturing, services). > Focus on small/mid-caps: Beyond the leaders, consider biotech ETFs to capture U.S. small/mid-cap innovators with M&A potential. > - Dynamic tracking: Monitor the final version of U.S. executive orders, FDA guidelines, and Chinese pharma responses (e.g., European JVs, plant construction), as these will be key stock price drivers. > - Valuation awareness: Some beneficiaries may have already priced in expectations; assess valuation rationality before entry. > - Risk reminder: Policy uncertainty remains the biggest variable. Escalating geopolitical tensions could spill over to European firms. Always assess personal risk tolerance before investing. ### Related Stocks - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) - [REGN.US](https://longbridge.com/en/quote/REGN.US.md) - [BNTX.US](https://longbridge.com/en/quote/BNTX.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [DHR.US](https://longbridge.com/en/quote/DHR.US.md) - [IQV.US](https://longbridge.com/en/quote/IQV.US.md) - [CRL.US](https://longbridge.com/en/quote/CRL.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) - [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) ## Comments (13) - **股海頑童 · 2025-09-30T20:31:59.000Z**: Thanks for sharing! - **名字什么的都是代号 · 2025-09-12T05:02:34.000Z**: Unit price... - **济无咎 · 2025-09-12T03:05:20.000Z · 👍 4**: In terms of local R&D, $Vertex Pharma(VRTX.US) has a compelling story to tell, as cystic fibrosis is more prevalent among Caucasians. Other conditions like SLE and IBD, which are also more common among Caucasians, do not yet have a dominant player like VRTX.— Mentioning a smaller company, $Abiva - **Tui · 2025-09-12T01:23:11.000Z**: What about HIMS? I plan to buy it when it pulls back. - **天蝎投资学习历程 · 2025-09-12T01:15:30.000Z**: Bookmark first, then read - **奇迹的交易员cola · 2025-09-12T01:13:20.000Z · 👍 2**: $Intuitive Surgical(ISRG.US) is undoubtedly a great company. But this time, it mainly refers to the biotech category 🏂 - **Mega大队长 · 2025-09-12T01:12:04.000Z · 👍 2**: What policies will Trump introduce? - **解套工程队监理 · 2025-09-12T01:10:57.000Z · 👍 1**: How about buying XBI directly? - **奇迹的交易员cola** (2025-09-12T01:14:31.000Z): Also pretty good🤔 - **奇迹的交易员cola · 2025-09-12T01:10:35.000Z · 👍 2**: @济无咎 Could you please take a look? 🤔 - **長野原烟花店交易员 · 2025-09-12T01:10:18.000Z · 👍 5**: I'll mention one, ISRG Intuitive Surgical. Their equipment is top-notch, and many high-end devices in private hospitals are from them. Then there's also some kind of AI surgical robot. - **奇迹的交易员cola** (2025-09-12T01:11:45.000Z): Da Vinci System. - **長野原烟花店交易员** (2025-09-12T01:13:12.000Z): Well, I think it's quite similar to ASML. Absolute monopoly.